Clinical Trials | December 31, 2025
GenSight Biologics gets early access nod for candidate gene therapy in Israel
Applications include detailed scientific rationale and supporting clinical evidence
Applications include detailed scientific rationale and supporting clinical evidence
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This recognition demonstrate excellence in intellectual property (IP) value creation.
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Subscribe To Our Newsletter & Stay Updated
